• 1
    The U. S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 11101115.
  • 2
    Colonna J, Goldstein L, Brems J, Vargas J, Brill J, Berquist W, Hiatt J, et al. A prospective study on the use of monoclonal anti-T3-cell antibody (OKT3) to treat steroid-resistant liver transplant rejection. Arch Surg 1987; 122: 11201123.
  • 3
    Solomon H, Gonwa T, Mor E, Holman M, Gibbs J, Watemberg I, Netto G, et al. OKT3 rescue for steroid-resistant rejection in adult liver transplantation. Transplantation 1993; 55: 8791.
  • 4
    Nozaki H. Experimental study on the effect of ursodeoxycholic acid in liver transplantation. J Jpn Surg Soc 1992; 93: 14811488.
  • 5
    Persson H. Friman S, Schersten T, Svanvik J, Karlberg I. Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients. Lancet 1990; 336: 5253.
  • 6
    Friman S, Persson H, Schersten T, Svanvik J, Karlberg I. Adjuvant treatment with ursodeoxycholic acid reduces acute rejection after liver transplantation. Transplantation Proc 1992; 24: 389390.
  • 7
    Sharara AI, Camargo CA, Clavien PA. Ursodeoxycholic acid prevents steroid resistant rejection in liver transplant recipients. Gastroenterology. 1995; 108: A1168.
  • 8
    Cirillo N, Zwas F. Ursodeoxycholic acid in the treatment of chronic liver disease. Am J Gastroenterol 1994; 89: 14471452.
  • 9
    Heathcote EJ, Cauch-Dudek K, Walker V, Bailey R, Blendis L, Ghent C, Michieletti P, et al. The Canadian multicenter double-blind randomized controlled trial of Ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19: 11491156.
  • 10
    Poupon R, Poupon R, Balkau B, and the UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330: 13421347.
  • 11
    Lindor K, Dickson ER, Baldus W, Jorgensen R, Ludwig J, Murtaugh P, Harrison J, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 12841290.
  • 12
    Combes B, Carithers R, Maddrey W, Lin D, McDonald M, Wheeler D, Eigenbrodt E, et al. A randomized, double-blind, placebo-controlled trial of Ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22: 759766.
  • 13
    Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of Ursodeoxycholic acid. Hepatology 1990; 11: 1215.
  • 14
    Terasaki S, Nakanuma Y, Ogino H, Unoura M, Kobayashi K. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after Ursodeoxycholic acid therapy. Am J Gastroenterol 1991; 86: 11941199.
  • 15
    International Working Party. Terminology for hepatic allograft rejection. Hepatology 1995; 22: 648654.
  • 16
    Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1945; 1: 8083.
  • 17
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457481.
  • 18
    Peto R, Peto J. Assymptotically efficient rank invariant test procedures. J Royal Stat Soc Ser 1972; A135: 185198.
  • 19
    Al-Quaiz M, O'Grady J, Tredger J, Williams R. Variable effect of Ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. Transplant Int 1994; 7: 190194.
  • 20
    Pageaux G, Blanc P, Perrigault P. Failure of Ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation. J Hepatol 1995; 23: 119122.